Damora Therapeutics, Inc. DMRA
22.05 USD -1.20 (-5.16%)
Nov 12, 2026, 2:11 PM EST
21.83 Day range 23.04
15.76 52-week range 38.33
- YTD
- -4.17%
- 1 year
- -6.57%
- Market cap
- 1.36B
- EPS (ttm)
- 1.71
- Shares out
- 61.90M
- P/E ratio
- 12.89
- Forward P/E
- -10.64
- YTD return
- -4.17%
- 1-year return
- -6.57%
- Volume
- 257.25K
- Avg volume
- 547.75K
- Open
- 23.04
- Previous close
- 23.25
- Day's range
- 21.83 – 23.04
- 52-week range
- 15.76 – 38.33
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- 46.78 (+112.1%)
- Earnings date
- Mar 18, 2027
5D +2.43 (+10.88%)
Key statistics
- Enterprise value
- 1.10B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.55M
- Total cash
- 528.48M
- Total debt
- 1.10M
- Return on equity
- -115.80%
- Short % of float
- 8.84%
- 50-day average
- 22.54
- 200-day average
- 25.53
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.78 +112.1% upside
Now 22.05
- Target (low)
- 40.00
- Target (mean)
- 46.78
- Target (high)
- 59.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 18, 2027
Expected Mar 18, 2027. Consensus EPS estimate -0.47.
Financials — quick view
DMRA Revenue — quarterly 0
DMRA Net income — quarterly -31.99M
DMRA EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 18, 2027 | Dec 30, 2026 | -0.55166 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.48251 | -0.40 | +0.08 | +17.10% |
| Aug 11, 2026 | Jun 30, 2026 | -0.41395 | -0.39 | +0.02 | +5.79% |
| May 12, 2026 | Mar 31, 2026 | -0.21 | -0.62 | -0.41 | -195.24% |
| Mar 18, 2026 | Dec 31, 2025 | -0.14 | -3.24 | -3.10 | -2,216.35% |
| Nov 6, 2025 | Sep 30, 2025 | -0.09681 | -2.36 | -2.26 | -2,337.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 25, 2026 | Guggenheim | main | Buy | Buy |
| Jul 30, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 27, 2026 | Jefferies | init | — | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- damoratx.com
News
Guggenheim Maintains Buy on Damora Therapeutics, Lowers Price Target to $59 
Damora Therapeutics Q3 EPS $(0.40) Beats $(0.48) Estimate 
Damora Therapeutics’ Preclinical Data Highlighting Potential Of DMR-001 Accepted For Poster Presentation At 2026 ASH Annual Meeting And Exposition 
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday 
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target 
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60 
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate - Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40 
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Your note
Sign in to keep a note on DMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNO JULIANNE | Director | Conversion of Exercise of derivative security | Feb 8, 2026 | 137,032 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| FIRMANI LORI | Chief Financial Officer | Sale | Jan 1, 2026 | 931 |
| HEWES LEMUEL BECKER | Officer | Stock Award(Grant) | Jan 4, 2026 | 264,629 |
| JARRETT A JENNIFER | Chief Executive Officer | Purchase | Sep 24, 2026 | 512,500 |
| SATTARZADEH SHERWIN | Chief Operating Officer | Stock Award(Grant) | Jan 4, 2026 | 190,376 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.43% | 9,549,056 | 222.02M | Sep 29, 2026 |
| Geode Capital Management, LLC | 1.94% | 1,203,286 | 27.98M | Sep 29, 2026 |
| UBS Group AG | 1.75% | 1,082,845 | 25.18M | Sep 29, 2026 |
| Bank of Montreal /CAN/ | 0.33% | 205,519 | 4.78M | Sep 29, 2026 |
| Bank Of New York Mellon Corporation | 0.23% | 143,750 | 3.34M | Sep 29, 2026 |
| Nuveen, LLC | 0.23% | 141,509 | 3.29M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.96% | 1,835,051 | 42.66M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.98% | 1,227,145 | 28.53M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.35% | 834,040 | 19.39M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 723,719 | 16.83M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.94% | 584,529 | 13.59M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.87% | 540,246 | 12.56M | Sep 29, 2026 |